Apollomics
- Country
- ππ°Hong Kong, China
- Ownership
- -
- Employees
- 45
- Market Cap
- -
- Introduction
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05367388
- Locations
- π³πΏ
New Zealand Clinical Research, Auckland, New Zealand
APL-102 Capsule in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: APL-102 Capsules
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05055518
- Locations
- π¨π³
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05054543
- Locations
- π¨π³
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
π¨π³The First Affiliated Hospital of Zhejiang University, Hangzhou, China
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04839341
- Locations
- π¨π³
The First Affiliated Hospital of Zhejiang University, Hangzhou, China
π¨π³Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, Tianjin, China
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Conditions
- Gastroesophageal Junction AdenocarcinomaNSCLCLung CancerBrain TumorGlioblastoma MultiformeEGFR Gene MutationSolid TumorsAdvanced CancerRenal CancerMET Alteration
- Interventions
- Drug: APL-101 Oral Capsules
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Apollomics Inc.
- Target Recruit Count
- 497
- Registration Number
- NCT03175224
- Locations
- πΊπΈ
Loma Linda University Medical Center, Loma Linda, California, United States
πΊπΈWest Virginia University Cancer Institute, Morgantown, West Virginia, United States
πΊπΈOhio Health Research Institute, Columbus, Ohio, United States